CA2734908A1 - Compositions of pd-1 antagonists and methods of use - Google Patents

Info

Publication number

CA2734908A1

CA2734908A1 CA2734908A CA2734908A CA2734908A1 CA 2734908 A1 CA2734908 A1 CA 2734908A1 CA 2734908 A CA2734908 A CA 2734908A CA 2734908 A CA2734908 A CA 2734908A CA 2734908 A1 CA2734908 A1 CA 2734908A1

Authority

CA

Canada

Prior art keywords

polypeptide

cancer

amino acids

compound

contiguous amino

Prior art date

2008-08-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 140
• 239000000203 mixture Substances 0.000 title claims abstract description 78
• 239000005557 antagonist Substances 0.000 title claims abstract description 57
• 239000003795 chemical substances by application Substances 0.000 claims abstract description 138
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 125
• 230000003389 potentiating effect Effects 0.000 claims abstract description 104
• 150000001875 compounds Chemical class 0.000 claims abstract description 86
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 81
• 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 79
• 230000019491 signal transduction Effects 0.000 claims abstract description 72
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 58
• 229960004397 cyclophosphamide Drugs 0.000 claims abstract description 52
• 201000011510 cancer Diseases 0.000 claims abstract description 43
• 238000011269 treatment regimen Methods 0.000 claims abstract description 36
• 208000035473 Communicable disease Diseases 0.000 claims abstract description 8
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 192
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 169
• 229920001184 polypeptide Polymers 0.000 claims description 164
• 239000012634 fragment Substances 0.000 claims description 152
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 147
• 150000001413 amino acids Chemical class 0.000 claims description 119
• 230000027455 binding Effects 0.000 claims description 108
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 103
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 102
• 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 91
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 91
• 239000003446 ligand Substances 0.000 claims description 90
• 108020001507 fusion proteins Proteins 0.000 claims description 73
• 102000037865 fusion proteins Human genes 0.000 claims description 73
• 229940124060 PD-1 antagonist Drugs 0.000 claims description 65
• 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 claims description 56
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 56
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 50
• 230000005867 T cell response Effects 0.000 claims description 47
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
• 230000000694 effects Effects 0.000 claims description 37
• 201000010099 disease Diseases 0.000 claims description 34
• 238000011282 treatment Methods 0.000 claims description 34
• 241000124008 Mammalia Species 0.000 claims description 33
• 230000001965 increasing effect Effects 0.000 claims description 33
• 238000006467 substitution reaction Methods 0.000 claims description 24
• -1 anthracyclines Chemical compound 0.000 claims description 22
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 17
• 230000001225 therapeutic effect Effects 0.000 claims description 16
• 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims description 14
• 239000003814 drug Substances 0.000 claims description 13
• 239000003937 drug carrier Substances 0.000 claims description 12
• 238000004519 manufacturing process Methods 0.000 claims description 12
• 206010009944 Colon cancer Diseases 0.000 claims description 11
• 108060003951 Immunoglobulin Proteins 0.000 claims description 10
• 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 10
• 102000018358 immunoglobulin Human genes 0.000 claims description 10
• 210000003289 regulatory T cell Anatomy 0.000 claims description 10
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
• 229960004679 doxorubicin Drugs 0.000 claims description 9
• 208000015181 infectious disease Diseases 0.000 claims description 9
• 239000003112 inhibitor Substances 0.000 claims description 9
• 239000003886 aromatase inhibitor Substances 0.000 claims description 8
• 239000000539 dimer Substances 0.000 claims description 8
• 230000011278 mitosis Effects 0.000 claims description 8
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 7
• 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 7
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 7
• 229960001756 oxaliplatin Drugs 0.000 claims description 7
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 6
• 229940122815 Aromatase inhibitor Drugs 0.000 claims description 6
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 6
• 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 6
• 229940045799 anthracyclines and related substance Drugs 0.000 claims description 6
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 5
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
• 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 5
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 5
• 238000002648 combination therapy Methods 0.000 claims description 5
• 102000048362 human PDCD1 Human genes 0.000 claims description 5
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 5
• 229960002411 imatinib Drugs 0.000 claims description 5
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 5
• LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims description 5
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 5
• 229960001796 sunitinib Drugs 0.000 claims description 5
• 229940034785 sutent Drugs 0.000 claims description 5
• 206010033128 Ovarian cancer Diseases 0.000 claims description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
• 206010060862 Prostate cancer Diseases 0.000 claims description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
• 206010057644 Testis cancer Diseases 0.000 claims description 4
• 206010017758 gastric cancer Diseases 0.000 claims description 4
• 201000005787 hematologic cancer Diseases 0.000 claims description 4
• 239000000710 homodimer Substances 0.000 claims description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
• 201000002528 pancreatic cancer Diseases 0.000 claims description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
• 201000011549 stomach cancer Diseases 0.000 claims description 4
• 201000003120 testicular cancer Diseases 0.000 claims description 4
• 206010006187 Breast cancer Diseases 0.000 claims description 3
• 208000026310 Breast neoplasm Diseases 0.000 claims description 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
• 201000004101 esophageal cancer Diseases 0.000 claims description 3
• 201000005202 lung cancer Diseases 0.000 claims description 3
• 208000020816 lung neoplasm Diseases 0.000 claims description 3
• 239000000178 monomer Substances 0.000 claims description 3
• 201000000849 skin cancer Diseases 0.000 claims description 3
• 206010046766 uterine cancer Diseases 0.000 claims description 3
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 2
• 239000000833 heterodimer Substances 0.000 claims description 2
• 102000048776 human CD274 Human genes 0.000 claims description 2
• 206010005003 Bladder cancer Diseases 0.000 claims 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
• 206010038389 Renal cancer Diseases 0.000 claims 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
• 201000010881 cervical cancer Diseases 0.000 claims 2
• 201000010982 kidney cancer Diseases 0.000 claims 2
• 201000007270 liver cancer Diseases 0.000 claims 2
• 208000014018 liver neoplasm Diseases 0.000 claims 2
• 201000005112 urinary bladder cancer Diseases 0.000 claims 2
• 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
• 230000004044 response Effects 0.000 abstract description 16
• 230000001404 mediated effect Effects 0.000 abstract description 10
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 203
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 136
• 241000699670 Mus sp. Species 0.000 description 99
• 235000001014 amino acid Nutrition 0.000 description 95
• 229940024606 amino acid Drugs 0.000 description 84
• 238000002512 chemotherapy Methods 0.000 description 69
• 208000001088 cerebrotendinous xanthomatosis Diseases 0.000 description 68
• VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 description 68
• 210000004027 cell Anatomy 0.000 description 57
• 241000282414 Homo sapiens Species 0.000 description 44
• 108090000623 proteins and genes Proteins 0.000 description 28
• 229940044551 receptor antagonist Drugs 0.000 description 26
• 239000002464 receptor antagonist Substances 0.000 description 26
• 241001529936 Murinae Species 0.000 description 25
• 239000000427 antigen Substances 0.000 description 25
• 108091007433 antigens Proteins 0.000 description 25
• 102000036639 antigens Human genes 0.000 description 25
• 241000699666 Mus <mouse, genus> Species 0.000 description 23
• 102000005962 receptors Human genes 0.000 description 23
• 108020003175 receptors Proteins 0.000 description 23
• 102000004169 proteins and genes Human genes 0.000 description 21
• 230000028993 immune response Effects 0.000 description 20
• 235000018102 proteins Nutrition 0.000 description 20
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 19
• 108010076504 Protein Sorting Signals Proteins 0.000 description 18
• 238000002347 injection Methods 0.000 description 18
• 239000007924 injection Substances 0.000 description 18
• 230000014509 gene expression Effects 0.000 description 17
• 241000288906 Primates Species 0.000 description 15
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 14
• 230000003993 interaction Effects 0.000 description 14
• 108091008874 T cell receptors Proteins 0.000 description 13
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 13
• 210000004881 tumor cell Anatomy 0.000 description 13
• 229940045513 CTLA4 antagonist Drugs 0.000 description 12
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 12
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 239000002671 adjuvant Substances 0.000 description 11
• 230000004075 alteration Effects 0.000 description 11
• 229910052799 carbon Inorganic materials 0.000 description 11
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 230000004927 fusion Effects 0.000 description 11
• 239000012528 membrane Substances 0.000 description 10
• 150000003384 small molecules Chemical class 0.000 description 10
• 229960005486 vaccine Drugs 0.000 description 10
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• 230000000890 antigenic effect Effects 0.000 description 9
• 230000007423 decrease Effects 0.000 description 9
• 238000012217 deletion Methods 0.000 description 9
• 230000037430 deletion Effects 0.000 description 9
• 238000003780 insertion Methods 0.000 description 9
• 230000037431 insertion Effects 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 230000008029 eradication Effects 0.000 description 8
• 239000012678 infectious agent Substances 0.000 description 8
• 230000000670 limiting effect Effects 0.000 description 8
• 150000007523 nucleic acids Chemical group 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
• 125000000539 amino acid group Chemical group 0.000 description 7
• 230000002708 enhancing effect Effects 0.000 description 7
• 230000036039 immunity Effects 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• 229940124597 therapeutic agent Drugs 0.000 description 7
• 230000004614 tumor growth Effects 0.000 description 7
• 102000004127 Cytokines Human genes 0.000 description 6
• 108090000695 Cytokines Proteins 0.000 description 6
• 241000186781 Listeria Species 0.000 description 6
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 230000006052 T cell proliferation Effects 0.000 description 6
• 230000005975 antitumor immune response Effects 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 230000000139 costimulatory effect Effects 0.000 description 6
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
• 235000018417 cysteine Nutrition 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 239000002955 immunomodulating agent Substances 0.000 description 6
• 230000035772 mutation Effects 0.000 description 6
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• 101150051188 Adora2a gene Proteins 0.000 description 5
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 5
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• 208000036142 Viral infection Diseases 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 5
• 229940121354 immunomodulator Drugs 0.000 description 5
• 238000002513 implantation Methods 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000011081 inoculation Methods 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 239000008194 pharmaceutical composition Substances 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• 108010074708 B7-H1 Antigen Proteins 0.000 description 4
• 102000008096 B7-H1 Antigen Human genes 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 4
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 101001117311 Mus musculus Programmed cell death 1 ligand 2 Proteins 0.000 description 4
• 229930012538 Paclitaxel Natural products 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
• 239000004473 Threonine Substances 0.000 description 4
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 108010004469 allophycocyanin Proteins 0.000 description 4
• 230000000692 anti-sense effect Effects 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 230000000875 corresponding effect Effects 0.000 description 4
• 210000004443 dendritic cell Anatomy 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 235000013922 glutamic acid Nutrition 0.000 description 4
• 239000004220 glutamic acid Substances 0.000 description 4
• 229960001101 ifosfamide Drugs 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 206010022000 influenza Diseases 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
• 229960000310 isoleucine Drugs 0.000 description 4
• 229960003881 letrozole Drugs 0.000 description 4
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 229960001592 paclitaxel Drugs 0.000 description 4
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 229960000875 trofosfamide Drugs 0.000 description 4
• UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 4
• 230000009385 viral infection Effects 0.000 description 4
• ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 3
• 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 3
• 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 108010058846 Ovalbumin Proteins 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 230000005809 anti-tumor immunity Effects 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 235000009697 arginine Nutrition 0.000 description 3
• 235000003704 aspartic acid Nutrition 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 229940022399 cancer vaccine Drugs 0.000 description 3
• 238000009566 cancer vaccine Methods 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 229950011595 glufosfamide Drugs 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 230000002434 immunopotentiative effect Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 229960005386 ipilimumab Drugs 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 3
• 239000002773 nucleotide Substances 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 229940092253 ovalbumin Drugs 0.000 description 3
• VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 3
• 229950009351 perfosfamide Drugs 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 208000023958 prostate neoplasm Diseases 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 230000001629 suppression Effects 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 210000003462 vein Anatomy 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• QMGUSPDJTPDFSF-UHFFFAOYSA-N Aldophosphamide Chemical compound ClCCN(CCCl)P(=O)(N)OCCC=O QMGUSPDJTPDFSF-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 241000498849 Chlamydiales Species 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• 102000005720 Glutathione transferase Human genes 0.000 description 2
• 108010070675 Glutathione transferase Proteins 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 108010034145 Helminth Proteins Proteins 0.000 description 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
• 108090000144 Human Proteins Proteins 0.000 description 2
• 102000003839 Human Proteins Human genes 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 241000204031 Mycoplasma Species 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
• 241000606701 Rickettsia Species 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 2
• 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
• 108010081667 aflibercept Proteins 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 229940046844 aromatase inhibitors Drugs 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 229940120638 avastin Drugs 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 150000001718 carbodiimides Chemical class 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000013043 chemical agent Substances 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 238000011284 combination treatment Methods 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 230000001351 cycling effect Effects 0.000 description 2
• YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 229960000640 dactinomycin Drugs 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 244000000013 helminth Species 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 229950000547 mafosfamide Drugs 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 244000000010 microbial pathogen Species 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 201000009240 nasopharyngitis Diseases 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 229960003301 nivolumab Drugs 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 230000002381 testicular Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 210000003932 urinary bladder Anatomy 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 239000002525 vasculotropin inhibitor Substances 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• CQEQYBJQFPXKPE-AWEZNQCLSA-N (2s)-3-(2-bromoethyl)-n-(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound ClCCN[P@]1(=O)OCCCN1CCBr CQEQYBJQFPXKPE-AWEZNQCLSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• HGLRIYIVJRXBQM-UHFFFAOYSA-N 2-[2-[amino-[bis(2-chloroethyl)amino]phosphoryl]oxyethyl]-1,3-thiazinane-4-carboxylic acid Chemical compound ClCCN(CCCl)P(=O)(N)OCCC1NC(C(O)=O)CCS1 HGLRIYIVJRXBQM-UHFFFAOYSA-N 0.000 description 1
• KEPIZHRUELMLLO-UHFFFAOYSA-N 2-[2-[amino-[bis(2-chloroethyl)amino]phosphoryl]oxyethyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound ClCCN(CCCl)P(=O)(N)OCCC1NC(C(O)=O)CS1 KEPIZHRUELMLLO-UHFFFAOYSA-N 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• VJINKBZUJYGZGP-UHFFFAOYSA-N 3-(1-aminopropylideneamino)propyl-trimethylazanium Chemical compound CCC(N)=NCCC[N+](C)(C)C VJINKBZUJYGZGP-UHFFFAOYSA-N 0.000 description 1
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• WVKOPZMDOFGFAK-UHFFFAOYSA-N 4-hydroperoxycyclophosphamide Chemical compound OOC1=NP(O)(N(CCCl)CCCl)OCC1 WVKOPZMDOFGFAK-UHFFFAOYSA-N 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 241000186046 Actinomyces Species 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 241000192542 Anabaena Species 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 108010035053 B7-1 Antigen Proteins 0.000 description 1
• 102000038504 B7-1 Antigen Human genes 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 241000606125 Bacteroides Species 0.000 description 1
• 241000604933 Bdellovibrio Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 241000588807 Bordetella Species 0.000 description 1
• 241000589968 Borrelia Species 0.000 description 1
• 244000056139 Brassica cretica Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 241000589876 Campylobacter Species 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000222178 Candida tropicalis Species 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 241000863012 Caulobacter Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 241000191366 Chlorobium Species 0.000 description 1
• 241000190831 Chromatium Species 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 201000007336 Cryptococcosis Diseases 0.000 description 1
• 241000221204 Cryptococcus neoformans Species 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 241000605056 Cytophaga Species 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• 230000007118 DNA alkylation Effects 0.000 description 1
• 230000000970 DNA cross-linking effect Effects 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
• 241000192093 Deinococcus Species 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 108010059378 Endopeptidases Proteins 0.000 description 1
• 102000005593 Endopeptidases Human genes 0.000 description 1
• 241000224432 Entamoeba histolytica Species 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000588722 Escherichia Species 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 241000589601 Francisella Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 241000699694 Gerbillinae Species 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 241000606790 Haemophilus Species 0.000 description 1
• 241000205062 Halobacterium Species 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 241000228402 Histoplasma Species 0.000 description 1
• 241000228404 Histoplasma capsulatum Species 0.000 description 1
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
• 101000841411 Homo sapiens Protein ecdysoneless homolog Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 241000430519 Human rhinovirus sp. Species 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 241000862974 Hyphomicrobium Species 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 241001500351 Influenzavirus A Species 0.000 description 1
• 102100022338 Integrin alpha-M Human genes 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• BKCJZNIZRWYHBN-UHFFFAOYSA-N Isophosphamide mustard Chemical compound ClCCNP(=O)(O)NCCCl BKCJZNIZRWYHBN-UHFFFAOYSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 241000222722 Leishmania <genus> Species 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 206010027457 Metastases to liver Diseases 0.000 description 1
• 241000202974 Methanobacterium Species 0.000 description 1
• 241000192041 Micrococcus Species 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• 241000863420 Myxococcus Species 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 241000588653 Neisseria Species 0.000 description 1
• 241000605159 Nitrobacter Species 0.000 description 1
• 241000187678 Nocardia asteroides Species 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 241000192497 Oscillatoria Species 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 241000223960 Plasmodium falciparum Species 0.000 description 1
• 241001442539 Plasmodium sp. Species 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920002873 Polyethylenimine Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 241000606726 Rickettsia typhi Species 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 241000242680 Schistosoma mansoni Species 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 241000589973 Spirochaeta Species 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• 241000205101 Sulfolobus Species 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 241000204667 Thermoplasma Species 0.000 description 1
• 241000605118 Thiobacillus Species 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
• 241000589886 Treponema Species 0.000 description 1
• 241000224527 Trichomonas vaginalis Species 0.000 description 1
• 241000223105 Trypanosoma brucei Species 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
• 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 241000607598 Vibrio Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241000607734 Yersinia <bacteria> Species 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 159000000013 aluminium salts Chemical class 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 238000011230 antibody-based therapy Methods 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 229940030156 cell vaccine Drugs 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 238000011342 chemoimmunotherapy Methods 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
• 229960000928 clofarabine Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 230000008094 contradictory effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229950006799 crisantaspase Drugs 0.000 description 1
• 238000012926 crystallographic analysis Methods 0.000 description 1
• 150000003972 cyclic carboxylic anhydrides Chemical class 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 239000007862 dimeric product Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 229940066758 endopeptidases Drugs 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 229940007078 entamoeba histolytica Drugs 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000001808 exosome Anatomy 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000009760 functional impairment Effects 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• PSVUJBVBCOISSP-UHFFFAOYSA-N glufosfamide Chemical compound OCC1OC(OP(=O)(NCCCl)NCCCl)C(O)C(O)C1O PSVUJBVBCOISSP-UHFFFAOYSA-N 0.000 description 1
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 230000009675 homeostatic proliferation Effects 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 102000047791 human ECD Human genes 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229940090411 ifex Drugs 0.000 description 1
• 150000002463 imidates Chemical class 0.000 description 1
• HOPZBJPSUKPLDT-UHFFFAOYSA-N imidazo[4,5-h]quinolin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=C1 HOPZBJPSUKPLDT-UHFFFAOYSA-N 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000001524 infective effect Effects 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 238000010212 intracellular staining Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 230000001678 irradiating effect Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 201000006512 mast cell neoplasm Diseases 0.000 description 1
• 238000013411 master cell bank Methods 0.000 description 1
• 208000006971 mastocytoma Diseases 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 229960004635 mesna Drugs 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
• NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 230000004879 molecular function Effects 0.000 description 1
• 230000003232 mucoadhesive effect Effects 0.000 description 1
• 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 125000000405 phenylalanyl group Chemical group 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920002627 poly(phosphazenes) Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 229920002704 polyhistidine Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920000056 polyoxyethylene ether Polymers 0.000 description 1
• 229940051841 polyoxyethylene ether Drugs 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 210000004896 polypeptide structure Anatomy 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000009290 primary effect Effects 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 229940021993 prophylactic vaccine Drugs 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 229960003581 pyridoxal Drugs 0.000 description 1
• 235000008164 pyridoxal Nutrition 0.000 description 1
• 239000011674 pyridoxal Substances 0.000 description 1
• 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
• 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
• 229960001327 pyridoxal phosphate Drugs 0.000 description 1
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 229960004432 raltitrexed Drugs 0.000 description 1
• 230000036647 reaction Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 190014017285 satraplatin Chemical compound 0.000 description 1
• 229960005399 satraplatin Drugs 0.000 description 1
• 230000009291 secondary effect Effects 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 206010040872 skin infection Diseases 0.000 description 1
• 231100000019 skin ulcer Toxicity 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 230000019635 sulfation Effects 0.000 description 1
• 238000005670 sulfation reaction Methods 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000010741 sumoylation Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 229940021747 therapeutic vaccine Drugs 0.000 description 1
• AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 229960003181 treosulfan Drugs 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 230000004565 tumor cell growth Effects 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 230000002476 tumorcidal effect Effects 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 239000000277 virosome Substances 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1